”Big pharmas don’t have the luxury …” - love this opinion of yours.
Barring an easy takeover, what will be a second best option for these behemoths then? Pay up with cold, hard cash and/or access to their infrastructure perhaps? Sounds good and makes a lot of sense to me, especially when quite a few will be going down patent cliffs in the next 3-5 years. The dollars will have to be big though, given how much near and mid-term potential this company’s portfolio of assets holds. It boggles the mind.
Only a matter of time - in short order, dare we say?
DYOR, make up your own mind.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $2.012B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.57 | $6.922M | 4.377M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 81831 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |